RxDoctor Payments Data

Sierra Lee, NP

Family · Woodsboro, MDNPI 1700458437

Payments from drug & device makers

$1,836in general payments, 2019–2025

Across 94 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Novo Nordisk$356
  • Boehringer Ingelheim$238
  • AstraZeneca$195
  • Axsome Therapeutics, Inc.$130
  • Abbott$90
  • plus $445 from 14 others

What the payments were for

  • Food & beverage$1,836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,836 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$71,792
Medicare patients
300
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$30,775
Tresiba Flextouch U-100Insulin Degludec14$9,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,126
Albuterol Sulfate HfaAlbuterol Sulfate43$1,095
Levothyroxine Sodium68$957
Rosuvastatin Calcium43$892
Atorvastatin Calcium90$851
Metronidazole12$671
Amlodipine Besylate66$625
Sertraline Hcl39$622
Olmesartan Medoxomil20$620
Gabapentin37$616
Duloxetine Hcl12$583
Trazodone Hcl22$542
Omeprazole41$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$238$30,77519 claims
GSKTrelegy Ellipta$52$7,12611 claims
Almatica Pharma LLCSertraline Hcl$18$62239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Woodsboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →